Party Leaders, Former St. Jude Exec Lead In Medtech Campaign Donations
This article was originally published in The Gray Sheet
Executive Summary
For the 2015-2016 congressional campaign election cycle, House and Senate party leaders, as well as incumbents sponsoring industry-supported bills, are attracting significant donations. But one of industry's own, former St Jude Medical employee Angie Craig, is making a run as a Democrat for a House seat in Minnesota's 2nd congressional district. She has received the most donations from industry, in particular from her former St Jude colleagues, campaign funding data compiled by The Gray Sheet shows.
You may also be interested in...
Surgeons Using PODs To Skirt Disclosure, Kickback Rules, Senators Say
Orthopedic and other device-implanting surgeons who participate in physician-owned distributorships are circumventing Stark Law and Sunshine Act requirements to "grant themselves a steady stream of income" by ordering the most expensive implants, and performing some unneeded surgeries, says a Senate Finance Committee report released May 10. It scrutinizes the impact on spine surgeons, in particular.
Senate Moves To Floor Phase For Innovation Bill; Postmarket Surveillance, LDTs Could Get Attention
The Senate HELP Committee passed more measures for its planned medical innovation bill, including one affecting FDA's issuance of guidances versus formal rulemaking, and another in support of the administration's Precision Medicine initiative at an April 6 markup. Leadership also promised later floor debate on laboratory-developed test regulations and a device postmarket surveillance bill.
Senate Will Tackle Separate Device Reform Bills As Part Of Innovation Agenda
Multiple bills focused on accelerating the path to market for devices will join safety legislation reforming the regulation of duodenoscopes in a slate of Senate bills that HELP Committee Chairman Lamar Alexander said will receive hearings in February, March and April. The legislation-by-legislation approach in the Senate differs from the broad-based 21st Century Cures package that advanced in the House.